Publication | Closed Access

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

UrologyRenal FunctionGenitourinary CancerMedicineRenal PathologyOncologyRadiation OncologyRenal Cell CancerQt IntervalBibf 1120